688236.SH
Beijing Chunlizhengda Medical Instruments Co., Ltd.
SSE · Healthcare · Medical - Devices · CN
CNY 14.24
−1.73%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 975.3M | 1.0B | 805.9M | 1.2B | 1.2B |
| Cost of Revenue | 342.4M | 355.1M | 269.0M | 332.6M | 288.1M |
| Gross Profit | 632.8M | 690.6M | 536.9M | 875.9M | 913.5M |
| Operating Expenses | |||||
| R&D Expense | 114.9M | 118.5M | 133.1M | 157.4M | 162.3M |
| SG&A Expense | 34.8M | — | — | — | — |
| General & Admin Expense | 43.4M | 52.3M | 45.3M | 44.5M | 38.8M |
| Selling & Marketing Expense | 167.7M | 198.2M | 240.2M | 383.1M | 391.5M |
| Other Expenses | 3.0M | — | — | — | — |
| Total Operating Expenses | 331.8M | 367.7M | 409.3M | 579.3M | 585.8M |
| Cost and Expenses | 674.3M | 722.9M | 678.2M | 912.0M | 873.9M |
| Operating Income (EBIT) | 310.0M | 302.2M | 130.7M | 306.0M | 328.9M |
| Non-Operating | |||||
| Interest Income | 6.5M | — | — | — | — |
| Interest Expense | 76.4K | — | — | — | — |
| Net Interest Income | 6.4M | — | — | — | — |
| Other Non-Op Income/Expense | (1.6M) | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 307.9M | 301.7M | 131.6M | 305.9M | 336.9M |
| Income Tax Expense | 29.8M | 29.1M | 6.9M | 28.1M | 29.2M |
| Bottom Line | |||||
| Net Income | 278.0M | 272.5M | 125.0M | 277.8M | 307.7M |
| Earnings from Cont. Ops | 278.1M | 272.6M | 124.7M | 277.8M | 307.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 278.0M | 272.5M | 125.0M | 277.8M | 307.7M |
| Per Share | |||||
| Basic EPS | CN¥0.72 | CN¥0.71 | CN¥0.33 | CN¥0.72 | CN¥0.80 |
| Diluted EPS | CN¥0.72 | CN¥0.71 | CN¥0.33 | CN¥0.72 | CN¥0.80 |
| Revenue Per Share | CN¥2.51 | CN¥2.72 | CN¥2.13 | CN¥3.13 | CN¥3.12 |
| Shares | |||||
| Basic Shares Outstanding | 388.2M | 383.9M | 378.8M | 385.9M | 384.6M |
| Diluted Shares Outstanding | 388.2M | 383.9M | 378.8M | 385.9M | 384.6M |
| Profitability Metrics | |||||
| EBITDA | 80.2M | 341.8M | 167.6M | 339.2M | 357.2M |
| D&A | 9.7M | 39.6M | 36.9M | 33.3M | 28.3M |
| EBIT | 70.5M | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026